AEON Biopharma (AEON) Insider Trading & Ownership $0.74 +0.05 (+6.81%) As of 03:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AEON Biopharma (NASDAQ:AEON) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage0.86%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$55.60KNumber OfInsiders Selling(Last 12 Months)0 Get AEON Insider Trade Alerts Want to know when executives and insiders are buying or selling AEON Biopharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address AEON Insider Buying and Selling by Quarter AEON Biopharma Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails5/20/2025Jost FischerDirectorBuy60,000$0.51$30,600.00 5/19/2025Jost FischerDirectorBuy50,000$0.50$25,000.00 (Data available from 1/1/2013 forward) AEON Insider Trading Activity - Frequently Asked Questions Who is on AEON Biopharma's Insider Roster? The list of insiders at AEON Biopharma includes Crown Holdings Grou Strathspey, and Jost Fischer. Learn more on insiders at AEON. What percentage of AEON Biopharma stock is owned by insiders? 0.86% of AEON Biopharma stock is owned by insiders. Learn more on AEON's insider holdings. Which AEON Biopharma insiders have been buying company stock? The following insider purchased AEON shares in the last 24 months: Jost Fischer ($55,600.00). How much insider buying is happening at AEON Biopharma? Insiders have purchased a total of 110,000 AEON shares in the last 24 months for a total of $55,600.00 bought. AEON Biopharma Key ExecutivesMr. Marc Forth (Age 53)Principal Financial Officer, President, CEO & Director Compensation: $948.75kMr. Alex Wilson (Age 37)Executive VP, Chief Legal Officer & Corporate Secretary Compensation: $517.4kDr. Chad K. Oh M.D. (Age 65)Chief Medical Officer Compensation: $561kMs. Jennifer Sy (Age 39)Principal Accounting Officer More Insider Trading Tools from MarketBeat Related Companies OnKure Therapeutics Insider Transactions Clearside Biomedical Insider Transactions BioXcel Therapeutics Insider Transactions Akari Therapeutics Insider Transactions Synergy CHC Insider Transactions Mural Oncology Insider Transactions CASI Pharmaceuticals Insider Transactions Kezar Life Sciences Insider Transactions MIRA Pharmaceuticals Insider Transactions Dyadic International Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksInsiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift45 Stocks Insiders Are Selling That Analysts Say BuyStrategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying This page (NASDAQ:AEON) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AEON Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AEON Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access